Yes, indeed. You may find the answer in a recent article from the A2ALL study which was published in Hepatology in 2011: "Liver Transplant Recipient Survival Benefit with Living Donation in the Model for Endstage Liver Disease Allocation Era" by Carl L. Berg et al.
Probably the best paper on this was from the A2ALL study: Berg CL et al: Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology. 2011 Oct;54(4):1313-21. doi: 10.1002/hep.24494.
They found that In the current MELD era analysis, candidates who enrolled in A2ALL with MELD15+, who did not have HCC, and who received LDLT, had markedly lower waiting list mortality compared to those waiting for, or receiving DDLT (HR 0.42, 95% CI 0.26–0.69; p=0.0006).
Yes, The A2ALL study group was able to demonstrate lower waitlist mortality even in patients wtih MELD down to 12 with living donor transplantation. It was published in 2011 I think in Hepatology and the first author was Carl Berg.
- Badges
- Science topic
- Similar topics
- Biological Science
- Anatomy
- Tissue